Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

U.S. reaches historic milestone of 1 million organ transplants

United Network for Organ Sharing

On this day, the United States achieved its 1 millionth organ transplant. This historic accomplishment was confirmed by United Network for Organ Sharing (UNOS), the nonprofit powering the U.S. organ donation and transplantation system under contract with the federal government and in partnership with the nationwide organ donation and transplant community. Of the million U.S. transplants performed, more than half have occurred since 2007, a sustained trend of system-wide increases made possible by the ongoing expansion of more equitable organ allocation policies, an increasing focus on non-traditional donors, collaborative efforts to increase donation, the continuous evolution of organ preservation techniques and other scientific breakthroughs. “The organ donation and transplant community has made lifesaving history together,” said Jerry McCauley, M.D., president of the UNOS Board of Directors. "We invite donor families, transplant recipients, candidates, living organ donors, physicians, professionals, volunteers, advocates and others touched by transplant to honor and celebrate the gifts that made this important milestone possible.” The first successful transplant took place in Boston in 1954. Over 41,000 transplants were performed nationwide in 2021, the most ever in a single year, more than double the number from 25 years ago and the 9th consecutive record-setting year for deceased donor transplants. "Achieving 1 million transplants is a tribute to the hard work and dedication of the donation and transplant community," said UNOS CEO Brian Shepard. "While one million is just a number, each one of those million is a person restored to their families and communities. While we celebrate, honor and reflect, the work continues to save even more lives, increase the effectiveness of our high-performing national system, and reach the next million." Continual system-wide expansion and improvement are also marked by greater equity, especially in kidney allocation, which accounts for more than 60 percent of total transplants. In 2021, 58 percent of all kidney recipients were patients of color – a 25 percent increase from 1988 driven by multiple policy and performance improvements, including the elimination of race-based calculations used to measure kidney function. UNOS is inviting the transplant community – comprised of thousands of organ donation and transplant professionals, patients, donors, family members and volunteers – to collaborate in pursuit of the next million transplants. Living It Forward is a national initiative led by UNOS in partnership with the nation’s organ donation and transplant community to further accelerate the pace of lifesaving transplantation while commemorating so many lives saved, recognizing those still waiting, and remembering those we have lost. Visit LivingItForward.org to read stories about some of the people behind the 1 million and see how the gift of life has allowed them to begin living it forward. UNOS encourages everyone to become part of our community by registering as an organ donor. One person can save up to eight lives through organ donation and change the lives of as many as 75 through tissue donation. Because only two percent of people die in a way that makes organ donation possible, the need is great. More than 100,000 people remain on the transplant waitlist. Please register today at RegisterMe.org/LivingItForward. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

September 09, 2022 01:05 PM Eastern Daylight Time

Image

Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?

NervGen Pharma

Finding the cure to Alzheimer’s has confounded researchers for decades. As a disease, Alzheimer’s is highly complex and has a wide range of symptoms, including sleeplessness, wandering, agitation, anxiety, aggression, restlessness and depression. Because there is no cure for Alzheimer’s to date, treatments are focused on easing symptoms. There are a variety of treatments that can slow down how quickly the disease gets worse, and that can improve brain performance for a period of time, but invariably the disease gets worse, and patients progress to severe disease. Hope for Alzheimer’s Patients? Despite the lack of a cure, the National Institute of Health recently published an article describing several medications in late-stage clinical trials that could relieve those with Alzheimer’s. In this article, the most hopeful drug mentioned was aducanumab. Aducanumab was developed by Biogen Inc. (NASDAQ: BIIB) and helps to reduce amyloid deposits in the brain. The ability to reduce amyloid deposits made aducanumab an extremely promising development in Alzheimer’s because research demonstrated that Alzheimer’s disease is associated with the production and buildup of amyloid deposits in the brain. Despite treating what researchers believed to be a root cause of Alzheimer’s, aducanumab did not demonstrate the ability to impact clinical symptoms or outcomes such as worsening of cognitive abilities or dementia. What Was The Problem With The Alzheimer’s Study? Earlier this year, in an article published in Science, Dr. Matthew Schragg suggested that research in one of the primary studies on how amyloid deposits are associated with Alzheimer’s disease used falsified evidence. The study in question was published in 2006 and has been cited in over 2,200 scientific papers since then. Its title, “A specific amyloid-beta protein assembly in the brain impairs memory,” left little to the imagination. For the next 1½ decades, this article would be one of the foundational resources for the amyloid hypothesis and Alzheimer’s research. Unfortunately, Schragg’s discovery of potential image manipulation in the 2006 study suggests that Sylvain Lesné and the rest of the researchers involved in the study may have altered images to make them support their hypothesis. In response to Schragg’s observation, science integrity consultant Dr. Elisabeth Bik said that the 2006 study in question led to a significant amount of wasted research money and effort and has generated a lot of false hope for patients. Although the final determination on the value of targeting amyloid is still up for some debate, there is no doubt that the data led to an over emphasis on research on the amyloid hypothesis to the detriment of other approaches. While there are currently drugs like Donepezil, produced by Pfizer Inc. (NYSE: PFE) and Eisai Co. Ltd. (OTCMKTS: ESALY), that helps some of the symptoms associated with dementia, there is still no cure for dementia to date. Where Does Alzheimer’s Research Go From Here? Biotech companies are researching alternative Alzheimer’s treatments that do not revolve around the research on amyloid deposits as the root of Alzheimer’s. These companies are opening up new and promising targets (pathways) to treating the disease that hadn’t been pursued in the past given the potentially flawed belief that amyloid deposits were the cause of the disease. One such company is NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF). NervGen’s technology is focused on mechanisms to repair damage to the brain and spinal cord. When there is damage to the nervous system, whether by injury or disease, there is a build-up of a class of chemicals called chondroitin sulfate proteoglycans (CSPGs). CSPGs play a key role in inhibiting the brain's own natural repair mechanisms. NervGen has developed a molecule, called NVG-291, that interferes with the inhibitory effects of the CSPGs, and that promotes the brain’s repair mechanisms, with some very dramatic results seen in preclinical disease models such as spinal cord injury and stroke. Of particular relevance to Alzheimer’s is research that has found an association between CSPGs and progression of the disease. The study looked at the levels of CSPGs in the brain in healthy aged subjects, patients with mild cognitive impairment, and patients with Alzheimer’s disease and found that the highest levels of CSPGs in the brain were found in Alzheimer’s patients, and the lowest levels were found in the healthy aged subjects. Some preclinical studies have found that breaking down CSPG deposits may help improve Alzheimer’s symptoms. Other studies have suggested that by removing the cellular receptor that CSPGs bind to, a protein known as tyrosine phosphatase sigma, may help improve cognitive function for Alzheimer’s patients. In response to these studies, NervGen says it developed NVG-291 to relieve the inhibitory effects of CSPGs, improving the function of neurons and strengthening the connection between neurons. While falsified data in major Alzheimer’s research is a legitimate cause for confusion and anger, it should not impact the tenacity with which researchers are looking for the cure. As NervGen CEO Paul Brennan put it, “The findings of image manipulation has no relationship at all with the science supporting the use of NVG-291 in Alzheimer’s disease, and in fact, it underlines the importance of taking a diversified approach to trying to solve it.” This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Nancy Thompson nancyt@vorticom.com Company Website https://nervgen.com/stock-information/

September 08, 2022 04:47 PM Eastern Daylight Time

Genomic Life Achieves 2-Year HITRUST Certification

Genomic Life

(Sept. 8, 2022) – Securing an individual's healthcare data is always a priority. But instilling trust in today’s environment means exceeding expectations with security measures. Genomic Life, a genome management company with a mission of providing genetic testing and personalizing cancer support services, earned HITRUST’s certified status for its information, security, and privacy on its digital Genomic Life platform. According to the 2021 Healthcare Data Breach Trend Report, hacking and information technology incidents targeting outpatient and specialty clinics have grown 41% in the past year. With the healthcare industry becoming more digitally integrated each year, it’s become increasingly critical to protect online healthcare data better. Genomic Life’s achievement of a high-level certification is a new milestone in protecting sensitive member data. Genomic Life completed its annual SOC 2 Type 2 engagements as of July 1, 2020. It recently accomplished a HITRUST and NIST CSF validated assessment as of May 6th, 2022 with a certified report date of August 6th, 2022. “Achieving the HITRUST certification puts us in company with an elite group of organizations worldwide who have also earned this designation,” said Coley Chavez, Vice President, Compliance and Operations, Genomic Life. HITRUST Risk-based, 2-year (r2) Certified status demonstrates that Genomic Life has met federal and state regulations and is appropriately managing risk. The HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls. “In today’s ever-changing threat landscape, HITRUST is continually innovating to find new and creative approaches to address challenges,” said Jeremy Huval, Chief Innovation Officer, HITRUST. “Genomic Life’s HITRUST Risk-based, 2-year Certification is evidence that they are at the forefront of industry best practices for information risk management and compliance.” The genome management program facilitates lifetime access to genomic insights. Members receive genetic tests to prevent disease through proactive genetic screening. The program also helps diagnose diseases more accurately and tailors services and treatments. “Security of our member information is paramount. With our platform, members will have the strongest degree of security measures in place safeguarding their information, providing one less worry for them,” said Karen Ferrell, CEO, Genomic Life. “I’m very proud of our team at Genomic Life who worked hard to attain the certifications that demonstrate the highest standards and that only a few select companies achieve.” ### About Genomic Life: Genomic Life accelerates the transition to genomics to deliver a proactive health ecosystem rooted in affordability, accessibility, and actionability. Understanding an individual's unique genome helps uncover health risks, informs treatment, and personalizes approaches to optimize health. Learn more here. Contact Details The Hoyt Organization Kelly Reynolds +1 310-343-3197 kreynolds@hoytorg.com Company Website https://genomiclife.com/

September 08, 2022 10:09 AM Pacific Daylight Time

Fine Hygienic Holding Wins License to Market FIFA World Cup Qatar 2022™ Fine Facial Tissues

Fine Hygienic Holding

Football's world governing body FIFA has awarded Fine Hygienic Holding (FHH) the license to design, produce, and sell limited-edition packs of facial tissues commemorating the FIFA World Cup Qatar 2022™. FHH will make the special edition packs available in hypermarkets and supermarkets in Jordan, Egypt, Saudi Arabia, the UAE, Bahrain, Oman, Kuwait, Iraq, Morocco and Sudan starting from mid-September. James Michael Lafferty, FHH CEO, said: “Being awarded the license for the FIFA World Cup Qatar 2022™ is a major milestone in our group’s journey. We are extremely proud to be part of such a significant moment for all of the world, and excited to contribute to the experience of football fans in the region by creating a high-quality product to celebrate the tournament.” The FIFA World Cup Qatar 2022™ will be the first World Cup ever to be held in the Arab World. It is scheduled to take place from November 20 to December 18, 2022, in Qatar, with matches being played across eight stadiums, hosting 32 teams. Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. FHH offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings innovative nutritional supplements, Motiva, to the market. Contact Details Action Global Communications Pragati Malik +971 54 531 5575 pragati.m@actionprgroup.com Company Website https://www.finehh.com/

September 08, 2022 11:30 AM Eastern Daylight Time

Image

NextFerm Technologies announces a strategic manufacturing agreement for the production of ProteVin™, its vegan protein, with a subcontractor in Europe

NextFerm Technologies Ltd.

The commissioning of the plant will be completed in the second half of 2023 with an annual production capacity of about $10M, with future expansion capacity to tens of millions of dollars per year The subcontractor will bear the costs of constructing the plant’s building and will provide all infrastructure and production services as well as the baker’s yeast necessary to produce ProteVin™. The company will bear the costs of purchasing and installing the equipment necessary for production The product was launched to several customers and the company has a wide range of food and dietary supplement companies including global companies, who are examining the integration of ProteVin™ in a variety of alternative products (Yokneam Illit, September 8, 2022) – NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, fermentation-based, non-GMO protein alternative and other innovative yeast-based nutrients, announced today a strategic manufacturing agreement for the production of ProteVin™ with a subcontractor in the Balkan region in Europe. This marks the achievement of the company’s third strategic milestone (out of five) set for 2022. According to the agreement, the manufacturing plant will enable, at first stage, the production of ProteVin™ with an annual capacity of up to $10M starting the second half of 2023. The plant commissioning plan enables a future expansion of the capacity to tens millions of dollars. This plant is expected to replace the current pilot production plant in GFR Canada. The subcontractor will establish the plant and will provide the production services as well as the baker’s yeast necessary to produce ProteVin™. The company will bear the costs of purchasing and installing the equipment necessary for production. The Company estimates that the necessary investment needed for the completion of the manufacturing plant and reaching the above mentioned capacity will be approximately $6M. The main equipment needed for the plant was already ordered. The agreement relates only for production services and doesn’t include IP transfer to the subcontractor. Boaz Noy, Chief Executive Officer of NextFerm, said: "This manufacturing agreement for the production of our vegan protein is an important milestone for our Company and represents the transition into an industrial company in the field of alternative proteins. The plant was designed in a way that would allow investment in the production capacity in accordance with the increase in demands. ProteVin™ is the only alternative protein on the market today with a neutral taste and an animal-like nutritional value, and we believe it will become a leading solution in the global alternative protein industry.” About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein with animal-like nutritional value (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 3.5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

September 08, 2022 09:00 AM Eastern Daylight Time

Biocidin Botanicals™ Launches Dentalcidin® Oral Care System, the First Dentaceutical™ Solution for Oral Microbiome Health

Biocidin Botanicals

Biocidin Botanicals ™, a pioneer in botanical supplements and microbiome health, announced today the launch of its two-step Dentalcidin ® Oral Care System. The system consists of the company’s reformulated and repackaged Dentalcidin® Oral Microbiome Toothpaste along with its Dentalcidin® LS Liposomal Rinse. Combining the toothpaste and oral rinse into a two-step system ensures comprehensive health benefits for customers. It also recognizes the science-backed connection between the oral microbiome and whole-body health. ( Learn more ) “We’re excited to take what we’ve learned over the past 30-plus years about microbiome health and apply it to the things we use every day, like toothpaste and mouth rinse,” said Rachel Fresco, L.Ac., Ph.D., Biocidin Botanicals’ Founder and Formulator. “Research continues to confirm that whole-body health starts in the mouth. These products are more than just toothpaste and mouthwash. We’ve coined a new term for it. They’re “Dentaceuticals ™” – natural dental formulations that improve the health of teeth and gums and ultimately support whole-body wellness. When used together, these products provide incredible health support!” Dentalcidin Oral Microbiome Toothpaste® has been available for several years. In response to customer feedback and keeping with the company’s sustainability goals, Biocidin Botanicals reformulated and repackaged the toothpaste this year, a decision that reflects its commitment to both people and planet. “As a company, we believe our choices matter,” Fresco said. “We care about our customers and listen to them. We also constantly evaluate our impact on the planet. That’s why we made the decision to reformulate the toothpaste to be 100% plant-based and to deliver it in a sleek, stand-up tube that is 100% recyclable. It’s easier to use and easier on the planet.” Both products in the Dentalcidin® Oral Care System are powered by the 18 botanical extracts and essential oils in Biocidin®, the company’s broad-spectrum, legacy formula. This clinically effective, evidence-based proprietary blend has been trusted by health professionals for over 32 years. Great Smokies Diagnostic Laboratories (now Genova Diagnostics) called it one of the most potent natural formulations they’ve ever analyzed. With other select botanicals providing added synergy and benefits, the entire system relies on a 100% natural, plant-based, and chemical-free ingredient list to give practitioners and consumers robust health benefits derived from the best botanical sources. The Dentalcidin® Oral Care System delivers the results usually associated with toothpaste and an oral rinse. It whitens teeth, freshens breath, and is gentle enough for sensitive teeth. But thanks to Biocidin Botanicals’ commitment to putting “Serious Science Behind Every Smile™,” its benefits go far beyond. Comprehensive university research, case studies, rigorous testing, and innovative formulation processes have resulted in a system with unique health benefits. The Dentalcidin® Oral Care System: Assists in removing oral biofilms (plaque) Utilizes liposomal technology for deeper penetration in the periodontal area* Supports gum and gingival health with targeted ingredients such as CoQ10, quercetin, clove, and myrrh* Provides tissue-soothing activity* Supports oral microbiome balance for whole-body health* Keeps teeth feeling clean and smooth all-day “This system really demonstrates the power of botanicals to support a balanced oral microbiome,” Fresco said. “Because oral health directly impacts systemic health, a balanced oral microbiome also supports whole-body health, including cognitive, respiratory, cardiovascular, gastrointestinal, and joint health. But the reverse is also true. Poor oral health impacts more than just your mouth. That motivated us to develop something uniquely powerful, an innovative Dentaceutical solution.” Dentists, dental hygienists, and integrative and functional practitioners recommend Dentalcidin® toothpaste and oral rinse. Functional dentist Dr. Ariana Ebrahimian says of the products, “I highly recommend Biocidin Botanicals’ oral care products to my patients and use the liposomal rinse in our scaling procedures. They are incredibly effective at busting up harmful biofilms in the mouth and rebalancing the oral microbiome without the harsh side effects of chemicals.” The launch of Biocidin Botanicals’ Dentalcidin™ Oral Care System is a true breakthrough in oral care, bolstering the company’s position as a thought leader and innovator in the botanical supplements space. ABOUT BIOCIDIN BOTANICALS ™ Biocidin Botanicals™ is a leader in botanical supplements and a pioneer in microbiome health. Its legacy broad-spectrum botanical blend Biocidin® was formulated in 1989 in response to challenging health conditions related to microbial imbalances. More than 30 years later, the company offers a curated line of targeted support products to boost patient health. Healthcare practitioners have utilized these clinically effective, evidence-based products for over three decades to help millions of patients achieve vibrant health and wellness. Biocidin Botanicals™ will continue to lead the way in functional and integrative medicine through its plant-powered products. Visit their website at www.biocidin.com or check them out on Instagram or LinkedIn for more information. Contact Details Biocidin Botanicals Susan Fecko +1 307-690-8381 sfecko@blackdogstudiopr.com Company Website https://biocidin.com/

September 08, 2022 08:30 AM Eastern Daylight Time

Image

Introducing the GE Safety Helmet with patented technology by Caco America LLC

Caco Abbo Internacional

Caco America LLC a subsidiary of Caco Abbo International, S.A., leader for more than 36 years in the PPE market with sales in more than 35 countries and the exclusive licensee of GE, for the design, manufacturing, and distribution of GE branded personal protective equipment (“PPE”) products for the Americas, is pleased to announce the launch of the GH400 safety helmet with a patented technology at the next NSC show September 2022 in San Diego, CA. Booth 2131. Caco America LLC is committed in bringing the best technologies and designs to the workforce to improve the occupational safety, health, and well-being of workers. The Future of the safety helmet has arrived with the GE branded, safety helmet (part number GH400). In partnership with Koroyd™ Technologies, Caco America has designed one of the lighter, smaller, and more breathable helmets in the industry. The GH400 protective helmet is engineered with the patented Koroyd™ impact-absorbing technology. Its cross-ventilation cooling feature and light weight provide the user with the most comfortable fit in the market. It facilitates the job through an array of accessories available and gives the user a better-looking style due to its lower profile design. Available vented or non-vented. Type 1, Class C, and Class E. Please see the complete GH400 protective helmet brochure here. At the trade show, Caco America will also be presenting the GG244-FUSEFLEX gloves with a patent pending TPR design that has an A5 cut resistant feature as well as an IMPACT 2 protection. The GG244 FUSEFLEX is a foam nitrile patent pending TPR Impact Glove. This glove has the latest in engineering TPR protection to provide flexibility, comfort, and protection all day long. The 18-gauge liner was developed to feel light and thin while providing ANSI cut level 5 protection (A5) due to the components of its fibers. Its black foam nitrile palm coating provides outstanding dexterity, enhanced grip, and touchscreen compatibility. For even more protection, it has a longer cuff and a stitched reinforced crotch thumb. Please see our complete catalog here. About Caco Abbo Caco Abbo Internacional, S.A. was founded in 1986 by Mr Isaac Abbo V and his son Jose M Abbo. In 1992 Joel Abbo joined the company and expanded the development of products and international sales. Today, Caco Abbo International, S.A. is one of the top Import/Export Companies in the Americas with sales in more than 35 countries. www.cacoamerica.com About GE GE (NYSE:GE) rises to the challenge of building a world that works. For more than 125 years, GE has invented the future of industry, and today the company's dedicated team, leading technology, and global reach and capabilities help the world work more efficiently, reliably, and safely. GE's people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill GE's mission and deliver for its customers. www.ge.com Contact Details Caco America LLC Isaac Joel Abbo +1 305-512-1150 sales@cacoamerica.com Company Website https://www.geppe.cacoamerica.com/

September 07, 2022 12:46 PM Eastern Daylight Time

Image

Local Lab Campaigns for Science-Backed Cannabis Policies, Business Practices

MCR Labs

Local cannabis testing and research laboratory MCR Labs will be leading open discussions on how to better inform cannabis policies, legislature, and cultivation through the use of data and science. As one of the first independent cannabis testing labs to be established in Massachusetts with the largest cannabis data set on the east coast, MCR Labs is uniquely positioned to guide these conversations. MCR Labs will host several events centered around sensible policy-making and industry standards. The campaign will culminate with MCR’s annual Cannabis Science Fair, showcasing the latest exciting cannabis research and innovation. “What we really need to get away from, especially on a legislative level, is allowing special interests and long-time stigmas to get in the way of sensible policy-making that protects consumers and patients,” said MCR Founder Michael Kahn. “It’s time objective data derived from sound science is used to inform this industry.” The campaign, titled “Science Over Stigma,” is sponsored by Boston Cannabis Week, an organization that curates a week of events for cannabis professionals, consumers and industry innovators. Set in September, Boston Cannabis Week will feature Science Over Stigma’s kick-off event “Cannabis Through the Ages” on Monday, September 19. Learn more about the campaign and upcoming events here. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

September 07, 2022 08:00 AM Eastern Daylight Time

Image

AliMed, Inc. awarded Pediatric Straps and Positioners agreement with Premier, Inc.

AliMed, Inc.

AliMed, Inc., a Massachusetts-based medical supply manufacturer and distributor, has been awarded a national group purchasing agreement for pediatric straps and positioners with Premier, Inc., and their Performance Group, Kiindo™. Effective June 1, 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for pediatric straps and positioners. “AliMed is committed to serving the pediatric community with high-quality healthcare products designed specifically for their needs,” said Adrienne Hamilton, Director of Marketing at AliMed. “We are excited about this agreement and look forward to working with Premier members to help them realize cost savings, improve efficiencies, and support better quality outcomes across the pediatric continuum of care.” With many products tailored to the unique needs of children from neonatal to adolescents, the AliMed contract includes imaging and surgical straps that provide support and stabilization without damaging delicate pediatric skin, surgical positioners appropriately sized to help relieve pressure from head to foot during procedures, and rehab positioners that aid with strengthening motor skills, balance, mobility, feeding, and more. Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 250,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting, and other services, Premier enables better care and outcomes at a lower cost. About AliMed AliMed, Inc. manufactures and distributes acute and post-acute medical products and devices. For over 50 years, AliMed has innovated to deliver flexible supply chain solutions with superior service and value-based products focused on the safety and productivity of the healthcare community. AliMed’s broad portfolio of products for domestic and international care providers, dealers, and distributors are designed to improve patient outcomes and experiences from “hospital to home.” Contact Details Katie McKinley, Sr. Marketing Product Manager, ORMI 781-329-2900 x 214 kmckinley@alimed.com

September 06, 2022 09:00 AM Eastern Daylight Time

Image

1 ... 204 205 206 207 208 ... 302